IL-34 is a 39–42 kDa homodimer composed of two non-covalently linked 222-amino acid subunits . It lacks a classical signal peptide but is secreted via an unconventional pathway. The protein forms a six-helix bundle structure and binds exclusively to the colony-stimulating factor 1 receptor (CSF1R), a receptor tyrosine kinase shared with CSF-1 .
Tissue/Organ | IL-34 Expression Level | Key Cell Sources |
---|---|---|
Spleen | Highest | Red pulp myeloid cells |
Intestine (Ileum) | Elevated in IBD | Stromal, epithelial cells |
Colon | Moderate | Lamina propria cells |
Brain | Constitutive | Microglia precursors |
IL-34 modulates immune responses through crosstalk between stromal and immune cells.
IL-34 is overexpressed in IBD, particularly in the ileum, where it drives TNF-α and IL-6 production via MAPK and NF-κB pathways . In experimental colitis, IL-34 blockade reduces inflammation by suppressing chemokine (CCL20) and cytokine release .
IL-34 promotes regulatory T cell (Treg) expansion. In humanized GVHD models, IL-34-differentiated monocytes enhance CD4⁺ and CD8⁺ FOXP3⁺ Treg generation, outperforming CSF-1 in suppressing immune responses .
Parameter | IL-34 | CSF-1 |
---|---|---|
Treg Expansion Efficiency | Superior (CD4⁺/CD8⁺) | Moderate (CD4⁺ only) |
Mechanism | ERK1/2 phosphorylation | Similar, but weaker effects |
GVHD Suppression | Enhanced survival | Limited efficacy |
IL-34’s dual role in promoting inflammation and inducing Tregs presents both opportunities and challenges for therapeutic targeting.
Autoimmune Diseases: Neutralizing IL-34 in IBD or rheumatoid arthritis to reduce pro-inflammatory cytokines.
Cancer Immunotherapy: Exploiting IL-34’s ability to enhance Treg-mediated tumor tolerance, though this may require context-specific modulation.
Tissue-Specific Effects: IL-34’s role varies between organs (e.g., protective in Alzheimer’s vs. harmful in IBD) .
Receptor Overlap: Off-target effects due to shared CSF1R with CSF-1 necessitate precise therapeutic design.
Future studies should focus on:
Receptor Specificity: Elucidating IL-34’s interaction with non-CSF1R receptors (e.g., CD138, PTPζ).
Disease Biomarkers: Validating IL-34 as a diagnostic marker for IBD or neurodegenerative diseases.
Treg Engineering: Optimizing IL-34-differentiated macrophages for adoptive Treg therapy in transplantation.
Interleukin 34 (IL34), a cytokine belonging to the interleukin family, plays a crucial role in the immune system. It primarily functions by promoting the differentiation and survival of monocytes and macrophages by interacting with the colony-stimulating factor-1 receptor. This interaction contributes to the growth and survival of these immune cells. IL34's influence extends beyond monocyte regulation, as it is believed to be involved in viral infection responses, adaptive immunity, and bone marrow cell proliferation. Moreover, IL34 is recognized for its significant contribution to innate immunity and inflammatory processes.
Recombinant Human IL34, produced in CHO cells, is a glycosylated homodimeric polypeptide chain with a molecular weight of 26kDa. It consists of 228 amino acids. The protein is engineered with a 6 amino acid His-tag at the C-terminus and undergoes purification using proprietary chromatographic techniques.
The product is lyophilized from a sterile (0.2µm) filtered solution containing phosphate buffered saline (PBS).
For reconstitution, it is recommended to dissolve the lyophilized IL34 in sterile water to a concentration of 0.1 mg/ml. This solution can be further diluted in other aqueous solutions as needed.
Lyophilized IL34 demonstrates stability at room temperature for up to 3 weeks. However, for optimal storage, it is recommended to store the lyophilized product desiccated below -18°C. After reconstitution, IL34 Human should be stored at 4°C for a period of 2-7 days. For long-term storage, it is advisable to store the reconstituted product below -18°C. The addition of a carrier protein, such as 0.1% HSA or BSA, is recommended for long-term storage. It's important to avoid repeated freeze-thaw cycles.
Interleukin 34, C16orf77, MGC34647, IL34
CHO cells.
NEPLEMWPLT QNEECTVTGF LRDKLQYRSR LQYMKHYFPI NYKISVPYEG VFRIANVTRLQRAQVSEREL RYLWVLVSLS ATESVQDVLL EGHPSWKYLQ EVETLLLNVQ QGLTDVEVSPKVESVLSLLN APGPNLKLVR PKALLDNCFR VMELLYCSCC KQSSVLNWQD CEVPSPQSCSPEPSLQYAAT QLYPPPPWSP SSPPHSTGSV RPVRAQGEGL LPHHHHHH
Human IL-34 is secreted as a homodimer consisting of 39 kDa monomers. It is synthesized as a 242 amino acid precursor that contains a 20 amino acid signal sequence and a 222 amino acid mature chain. The mature chain contains one potential site of N-linked glycosylation. The protein has no structural homology to any known cytokine family despite its functional similarities to CSF-1 . When working with recombinant human IL-34, researchers typically use the Asn21-Pro242 segment with a C-terminal 6-His tag for experimental studies .
Human IL-34 shares approximately 71% amino acid sequence identity with mouse IL-34 . This relatively high conservation across species suggests evolutionary importance of the protein's function. When designing cross-species experiments, researchers should consider these structural differences, especially when evaluating receptor binding affinity and downstream signaling events. Species-specific antibodies should be employed for accurate detection in mixed experimental systems.
IL-34 primarily functions as an alternative ligand for the colony-stimulating factor-1 receptor (CSF-1R). It stimulates monocyte proliferation and promotes the formation of colony-forming unit-macrophage (CFU-M), a macrophage progenitor, in human bone marrow cultures . In functional studies, IL-34 stimulates phosphorylation of extracellular signal-regulated kinase-1 and -2 (ERK1/2) in human monocytes, similar to CSF-1 . IL-34 and CSF-1 both support cell growth and survival of human monocytes and their differentiation into macrophages, though with some differences in polarization and cytokine production profiles .
IL-34 is expressed in various human tissues, with particularly high levels detected in the brain and skin where it is produced by neurons and keratinocytes, respectively . It is also expressed in heart, lung, liver, kidney, testes, intestine, thymus, spleen, colon, prostate, and lymph nodes . At the protein level, IL-34 has been detected in human skin, kidney, intestine, spleen, and brain . When designing tissue-specific experiments, researchers should consider these differential expression patterns, as they may indicate tissue-specific functions of IL-34.
Both IL-34 and CSF-1 are broadly expressed across various tissues, but their distribution patterns differ. CSF-1 mRNA is identified in human brain, spleen, testis, kidney, small intestine, lymph nodes, bone marrow, uterus, and ovary . IL-34 shows highest expression in brain and skin, with moderate expression in other tissues . This differential expression suggests that while both cytokines signal through the same receptor (CSF-1R), they may have distinct tissue-specific functions. When studying macrophage populations in specific tissues, researchers should consider analyzing both ligands to understand their relative contributions.
Human IL-34 primarily binds to the colony-stimulating factor-1 receptor (CSF-1R), which it shares with CSF-1 . Additionally, IL-34 can interact with alternative receptors: receptor-type protein-tyrosine phosphatase-ζ (PTP-ζ) and syndecan-1 (CD138), though the latter interaction occurs with lower affinity . PTP-ζ is expressed on neural progenitors, neurons, and glial cells in the central nervous system . For comprehensive receptor binding studies, researchers should employ surface plasmon resonance or similar techniques to quantify these differential binding affinities.
IL-34 plays a critical role in microglia development and maintenance in the central nervous system. While CSF-1 is essential for initial microglial development, IL-34 appears to regulate microglial homeostasis in a region-specific manner . In the retina, IL-34 expression by retinal ganglion cells controls the homeostasis of a specific subset of retinal microglia residing in the inner plexiform layer . IL-34 is also expressed by ependymal cells lining the ventricular system and in the choroid plexus, though its influence on choroid plexus macrophages requires further investigation . For studying microglia, researchers should consider brain region-specific analyses when evaluating IL-34 function.
Langerhans cells (LCs), the resident mononuclear phagocytes of the epidermis, are mostly derived from fetal liver monocytes and depend on IL-34 for their development and maintenance . IL-34 is produced by keratinocytes in the skin and is essential for LC homeostasis . When studying epidermal immune responses, researchers should consider the critical role of IL-34 in maintaining this specialized dendritic cell population and employ lineage tracing techniques to distinguish LC-specific effects.
Recombinant human IL-34 is typically supplied as a lyophilized protein. For the standard formulation containing BSA as a carrier protein, reconstitution should be performed at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin . For carrier-free formulations, reconstitution at 100 μg/mL in sterile PBS is recommended . The product should be stored immediately upon receipt at the recommended temperature, and repeated freeze-thaw cycles should be avoided by using a manual defrost freezer . For long-term stability studies, researchers should aliquot the reconstituted protein to minimize freeze-thaw cycles.
For studying IL-34 production in human tissues, researchers can employ a combination of techniques. At the mRNA level, quantitative RT-PCR provides sensitive detection of IL-34 expression patterns. For protein detection, ELISA, Western blotting, and immunohistochemistry are effective methods. Immunohistochemistry is particularly valuable for identifying the specific cell types producing IL-34 within complex tissues . Single-cell RNA sequencing technologies offer higher resolution insights into cell-specific expression patterns. When analyzing IL-34 expression, researchers should consider parallel analysis of CSF-1 expression to understand their relative contributions in specific contexts.
IL-34 expression is frequently altered in various autoimmune and inflammatory conditions. High expression of IL-34 correlates with disease severity in autoimmune diseases such as Sjögren's syndrome, systemic lupus erythematosus (SLE), psoriasis, and rheumatoid arthritis (RA) . In inflammatory diseases like liver fibrosis, IL-34 levels are also elevated . When studying these disease states, researchers should employ multiplex cytokine analysis to understand IL-34 expression in the context of the broader inflammatory milieu and consider longitudinal sampling to correlate with disease progression.
Given its high expression in the brain and importance for microglia, IL-34 plays significant roles in neuroinflammatory and neurodegenerative conditions. In prion disease models, IL-34 deficiency led to accelerated prion protein (PrPSc) deposition and shorter survival, suggesting a protective role . CSF-1R mutations associated with neurodegenerative diseases like adult-onset leukoencephalopathy with axonal spheroids and pigmented glia may involve disrupted IL-34 signaling . For studying neuroinflammatory conditions, researchers should consider region-specific analysis of IL-34 expression and microglia phenotypes using both imaging and flow cytometry approaches.
Though IL-34 and CSF-1 both signal through CSF-1R, they induce somewhat different functional outcomes in human monocytes. Both cytokines support monocyte survival and differentiation into macrophages, but IL-34 stimulation leads to higher production of IL-10 and CCL17, while CSF-1 induces greater MCP-1 expression . IL-34–stimulated macrophages also produce more eotaxin-1 compared to CSF-1–stimulated cells . These differential effects suggest distinct signaling mechanisms or receptor conformational changes induced by each ligand. For comparative studies, researchers should design time-course experiments with careful cytokine profiling to capture these differences.
Single-cell technologies like scRNA-seq, mass cytometry, and multiparameter flow cytometry can provide unprecedented insights into IL-34 biology . These approaches can reveal cell-specific expression patterns of IL-34 and its receptors, identify previously unknown cellular sources or targets of IL-34, and characterize the heterogeneity of cellular responses to IL-34 stimulation. When employing these technologies, researchers should include comprehensive panels of markers to identify rare cell populations and consider spatial transcriptomics to maintain information about tissue architecture and cellular interactions.
Interleukin-34 (IL-34) is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. It is a homodimeric protein that does not belong to any previously identified cytokine family. IL-34 is expressed by various tissues in response to inflammatory stimuli and has significant implications in hematopoiesis, immune response, and cellular differentiation.
IL-34 is a four-helical homodimeric protein. The human IL-34 protein is synthesized as a 242 amino acid precursor, which includes a 20 amino acid signal sequence and a 222 amino acid mature chain . It shares structural homology with macrophage colony-stimulating factor (M-CSF) and signals through the colony-stimulating factor receptor 1 (CSFR1) . This signaling pathway is essential for the expansion and differentiation of myeloid cells.
IL-34 has several critical biological functions:
Recombinant human IL-34 is produced using various expression systems, including HEK293 cells and mouse myeloma cell lines . It is optimized for use in cell culture, differentiation studies, and functional assays. The recombinant protein is typically purified to a high degree, with endotoxin levels below 0.1 ng/μg and purities greater than 95% .
Recombinant IL-34 has several applications in research and clinical studies: